| COVID-19 |
0 |
0.97 |
| Biologic Therapy |
0 |
0.94 |
| COVID-19 Vaccine |
0 |
0.8 |
| Cancer |
0 |
0.66 |
| Vaccines |
0 |
0.53 |
| Pneumonia |
0 |
0.51 |
| Covid-19 and Cancer |
0 |
0.5 |
| Immunization |
0 |
0.37 |
| Measles |
0 |
0.37 |
| Pediatric Respiratory Infections |
0 |
0.32 |
| Influenza Vaccine |
0 |
0.24 |
| Transplantation |
0 |
0.24 |
| Cell Transplantation |
0 |
0.19 |
| Immunocompromise |
0 |
0.18 |
| Outbreak |
0 |
0.18 |
| Pandemic |
0 |
0.18 |
| Stem Cell Research and Therapy |
0 |
0.18 |
| Chronic Lymphocytic Leukemia |
0 |
0.16 |
| CAR-T |
0 |
0.15 |
| Blood |
0 |
0.12 |
| Hematocrit |
0 |
0.12 |
| Multiple Myeloma |
0 |
0.12 |
| Severe Acute Respiratory Syndrome |
0 |
0.12 |
| Acute Respiratory Distress Syndrome |
0 |
0.1 |
| Acute Myeloblastic Leukemia |
0 |
0.09 |
| Chemotherapy |
0 |
0.09 |
| Child |
0 |
0.09 |
| Immunoglobulin G (IgG) |
0 |
0.09 |
| Leukemia |
0 |
0.09 |
| Plasma |
0 |
0.09 |
| Tumor |
0 |
0.09 |
| Myelodysplastic Syndrome |
0 |
0.08 |
| Acute Leukemia |
0 |
0.07 |
| Pneumococcal Vaccine |
0 |
0.07 |
| Clinical Research |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Ebola Virus |
0 |
0.05 |
| Influenza |
0 |
0.05 |
| Antigens |
0 |
0.03 |
| California |
0 |
0.03 |
| Dorsum |
0 |
0.03 |
| Hematology |
0 |
0.03 |
| Immunosuppressive Therapy |
0 |
0.03 |
| Immunotherapy |
0 |
0.03 |
| Monoclonal Antibody |
0 |
0.03 |
| Monoclonal Gammopathy |
0 |
0.03 |
| Neoplasm |
0 |
0.03 |
| Neutrophils |
0 |
0.03 |
| New York |
0 |
0.03 |
| Preventive Screening |
0 |
0.03 |
| T-Lymphocyte |
0 |
0.03 |